WEIGHT: 47 kg
Breast: DD
One HOUR:100$
NIGHT: +50$
Services: Deep Throat, BDSM, Slave, Golden shower (in), Uniforms
Official websites use. Share sensitive information only on official, secure websites. Integrins have become a target for novel therapeutic strategies against malignant gliomas. Using flow cytometry, we demonstrate that the target integrins of cilengitide are expressed not only in glioblastoma blood vessels, but also by tumor cells. After exposure of glioma cells to cilengitide, we noticed reduced phosphorylation of Smad2 in most glioma cell lines, including stem-like glioma cells.
Treatment of mice bearing experimental LN glioma xenografts with cilengitide results in reduced pSmad2 levels. Glioblastoma GBM is the most common and malignant primary brain tumor. GBM prognosis remains dismal despite available treatments, because of tumor recurrence.
In potential agreement with this possibility, primary cell cultures with characteristics of GSCs can be established from GBM. These cells display typical hallmarks of NSCs, namely unlimited self-renewal and ability to differentiate into different neural lineages in vitro.
Most importantly, GSCs are highly tumorigenic when transplanted intracranially in vivo and their in vitro self-renewal potential correlates positively with tumorigenicity and negatively with prognosis in glioma patients.
More importantly, mouse orthotopic implantations of human GSCs, which were either silenced for FOXG1 or overexpressing GRG6, gave rise to smaller tumors when compared to control condition; this tumor size reduction resulted in prolonged mice survival. Anti-angiogenic therapy holds promise for the treatment of Glioblastoma GBM , an aggressive brain tumor with dismal prognosis. However so far overall patient survival is barely improved and tumors quickly develop resistance mechanisms towards anti-angiogenic treatment.